

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
14 April 2005 (14.04.2005)

PCT

(10) International Publication Number
WO 2005/033056 A2

(51) International Patent Classification⁷: **C07C 51/00**

(21) International Application Number:
PCT/US2004/032918

(22) International Filing Date: 4 October 2004 (04.10.2004)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
60/509,678 8 October 2003 (08.10.2003) US
60/514,692 27 October 2003 (27.10.2003) US

(71) Applicant (for all designated States except US):
SMITHKLINE BEECHAM CORPORATION
[US/US]; One Franklin Plaza, PO Box 7929, Philadelphia,
PA 19101 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **EADDY, III, John,**
Fred [US/US]; GlaxoSmithKline, Five Moore Drive, PO
Box 13398, Research Triangle Park, NC 27709 (US).
HEYER, Dennis [US/US]; GlaxoSmithKline, Five Moore
Drive, PO Box 13398, Research Triangle Park, NC 27709
(US). **KATAMREDDY, Subba, Reddy** [IN/US]; Glaxo-
SmithKline, Five Moore Drive, PO Box 13398, Research
Triangle Park, NC 27709 (US). **MARTIN, Michael,**
Tolar [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
MCCLURE, Michael, Scott [US/US]; GlaxoSmithKline,
Five Moore Drive, PO Box 13398, Research Triangle Park,
NC 27709 (US). **RANDHAWA, Amarjit, Sab** [CA/US];
GlaxoSmithKline, Five Moore Drive, PO Box 13398,
Research Triangle Park, NC 27709 (US). **SAMANO,**

Vicente [US/US]; GlaxoSmithKline, Five Moore Drive,
PO Box 13398, Research Triangle Park, NC 27709 (US).
RAY, John, Albert [US/US]; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(74) Agents: **LEVY, David, J et al.**; GlaxoSmithKline, Five
Moore Drive, PO Box 13398, Research Triangle Park, NC
27709 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The present invention relates to novel compounds with a variety of therapeutic uses, more particularly novel prodrugs that are particularly useful for delivering a parent compound for selective estrogen receptor modulation.

WO 2005/033056 A2